Nobody expected a nearly three-hour documentary about Elizabeth Holmes to turn an R-rated DC Studios body-horror movie into a nail-biter at the multiplex. Yet that is exactly what happened across late October and early November 2026. When Clayface hit wide release on October 23, 2026, it entered a theatrical corridor already electric with word-of-mouth for You Can See Everything, co-directed by Nathan Fielder and Lance Oppenheim and distributed by A24.
The short answer to why Clayface faced such a real box-office fight comes down to timing, budget math, and an unusual collision of audiences. Clayface opened at number one domestically with $24 million across 3,458 theaters, while You Can See Everything surged in its second weekend with $18.7 million to $19.5 million as it expanded to 2,655 locations. A week later, during Halloween weekend, the documentary actually jumped into the domestic number-one spot with roughly $10.6 million to $11.4 million, edging Clayface by razor-thin margins. Learn more on a related issue: this related article.
If you look at headline box-office coverage, it is easy to read this clash as a David-versus-Goliath shock where a documentary humiliated a comic-book movie. Honestly, that framing misses what actually happened on the spreadsheet. Both films found real traction, and both exposed shifting habits in how people pick a movie on a Friday night.
How Clayface Entered the Fight With High Hopes and Tight Margins
DC Studios positioned Clayface as an adventurous, lower-budget detour inside Chapter One: Gods and Monsters. With a screenplay by Mike Flanagan and Hossein Amini (from Flanagan's story), direction by James Watkins, and producing muscle from Matt Reeves, Lynn Harris, James Gunn, and Peter Safran, the project looked like a smart bet on genre variety. Tom Rhys Harries stars as actor Matt Hagen, disfigured and reshaped through an experimental treatment developed by fringe scientist Dr. Caitlyn Corr (Naomi Ackie). Additional journalism by Vanity Fair delves into comparable perspectives on this issue.
Moving the release from September 11 to October 23 was a calculated play for fall and Halloween moviegoers. On paper, an R-rated body-horror tragedy starring a shapeshifter fits autumn nicely. In practice, that exact slot put Clayface right in the path of a documentary phenomenon that had already proved it could pack theaters.
Budget discipline helped keep Clayface afloat even when its domestic drop-offs looked steep. Reported production costs sit around $30 million to $44 million—a fraction of traditional superhero blockbusters. Its 54% to 57% second-weekend slide looked rough next to a leggy breakout, yet international ticket sales kept the global tally climbing past $120 million. When a mid-budget DC horror film crosses $120 million worldwide ahead of a November 27 theatrical debut in China, calling it a flop is just lazy narrative-chasing.
Still, there is a reason Clayface did not run away with October. Critics praised Rhys Harries's commitment—he filmed scenes despite a torn ACL—and the practical body-horror touches, while some reviewers felt the script and visual effects wavered. More importantly, Clayface was fighting for adventurous adults and horror fans who already had a hotter ticket circled on their calendar.
Why You Can See Everything Hit Like a Cultural Event
A documentary running 174 minutes about a convicted fraudster has no business drawing waves of Gen Z moviegoers to sold-out theatrical screenings. Yet You Can See Everything did exactly that after premiering as a secret screening at Telluride on September 6, 2026.
Part of the pull is the subject itself. Elizabeth Holmes remains a magnetic case study in hubris, self-mythology, and Silicon Valley illusion. Coverage around the film even noted viewership spikes for The Dropout, showing how audience curiosity around Holmes still ripples across platforms.
The bigger catalyst, though, is Nathan Fielder and Lance Oppenheim's approach. Fielder has built a fiercely loyal following around deadpan awkwardness, psychological theater, and meta-fiction, while Oppenheim brings a sharp, unsettling documentary eye. Rather than offering a straightforward true-crime recap, the film examines truth, media portrayal, and delusion—including reenactments with Amanda Seyfried reprising her The Dropout role as Holmes and Christopher Abbott as Billy Evans, alongside bizarre threads like AI-generated posts made while Holmes is behind bars.
You can see the momentum right in the numbers:
- Opening weekend (Oct 16–18): $15.6 million from just 855 theaters—an eye-popping per-theater average over $18,200.
- Second weekend (Oct 23–25): Up roughly 20% to around $18.7 million–$19.5 million across 2,655 locations, right as Clayface arrived.
- Third weekend (Oct 30–Nov 1): Claiming the domestic number-one spot with roughly $10.6 million–$11.4 million, the first non-musical documentary to hit number one since Fahrenheit 9/11 in 2004.
- Budget-to-box-office ratio: Grossing over $90 million worldwide on a reported $7 million budget.
That kind of return on investment changes how studios talk about risk. A24 turned a $7 million nonfiction gamble into a massive theatrical event, proving that when a film feels like an unmissable shared joke or conversation, people will leave their couches.
What This Clash Reveals About Modern Box Office Math
Watching Clayface and You Can See Everything trade blows highlights three truths about theatrical business in late 2026 that traditional pundits keep getting wrong.
First, IP alone does not guarantee dominance in a crowded month. Even a fresh, horror-inflected DC Studios entry has to earn urgency against a film people feel obligated to debate the next morning. A shapeshifting monster is fun; a slippery, meta-documentary about identity and deceit feels like a cultural Rorschach test.
Second, expansion strategy matters more than opening-weekend chest-thumping. You Can See Everything didn't blow its load on 4,000 screens on day one. Starting in 855 theaters created scarcity and strong theater averages, fueling organic word-of-mouth before expanding into thousands of rooms right as Clayface entered the frame. That staggered rollout kept the documentary alive through Halloween and well into November.
Third, profitability looks different at $40 million and $7 million than at $200 million. Neither film needed $500 million to justify its existence. Clayface built a global cushion above $120 million on a lean mid-budget footprint, while You Can See Everything became one of the highest-grossing documentaries ever on a shoestring cost. Both can claim real wins even while competing for the same weekend crown.
Where Both Titles Stand and What to Watch Next
As theatrical runs roll into late November 2026, the race has shifted from weekend-to-weekend bragging rights to long-tail reach. Clayface has wrapped up its primary North American run around the mid-$60 million mark while leaning on international markets—including its upcoming November 27 release in China—to push its worldwide total even higher. Meanwhile, You Can See Everything has pushed past $89 million domestically and over $90 million globally as international rollouts, including the UK, continue.
If you are deciding which one to prioritize—or tracking where the industry goes from here—take a few practical steps:
- Check local showtimes before they shrink: Both films are moving past peak screen counts in North America as fresh holiday/late-fall releases take over prime auditoriums. Catch whichever fits your taste on a big screen while screens remain open.
- Pair You Can See Everything with critical context: If you watch the documentary, look up reviews and background on how Fielder and Oppenheim structure its reenactments and archival claims—its whole tension lies in questioning reliability.
- Watch Clayface with horror expectations set right: Treat it as a dark, body-horror character study rather than a traditional cape-and-cowl spectacle, and pay attention to how DC Studios uses smaller genre swings to test future slate risks.
- Track overseas and awards traction: Watch how Clayface performs in China and whether You Can See Everything converts its massive box-office run into major awards-season buzz.